問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of Obstetrics & Gynecology

更新時間:2023-09-19

吳貞璇
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

6Cases

2025-03-01 - 2032-01-31

Phase III

Active
A phase 3, open-label, multicenter, randomized trial comparing trastuzumab deruxtecan plus bevacizumab versus bevacizumab alone as first-line maintenance therapy for HER2-positive ovarian cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13).
  • Condition/Disease

    Compare the efficacy of T-DXd plus bevacizumab (Group A) versus bevacizumab monotherapy (Group B) in the HER2 IHC 3+/2+ population, as assessed by BICR for progression-free survival (PFS).

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd、DS-8201a)

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2030-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2022-07-06 - 2026-12-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-12-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-06-11 - 2023-01-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2025-07-01 - 2029-06-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites